This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Keith Henry, MD; Barbara J. Chinnock; Richard P. Quinn, PhD; Courtney V. Fletcher, PharmD; Paulo de Miranda, PhD; Henry H. Balfour, Jr, MD

JAMA. 1988;259(20):3023-3026.

Abstract
Zidovudine was present in the semen and serum of six patients with acquired immunodeficiency syndrome or the related complex who were receiving 200 mg of the drug orally every four to six hours. Mean semen zidovudine levels (as measured by a new radioimmunoassay) in samples collected 0.75 to 1.25 hours after oral dosing were 3.63 to 7.19 µmol/L. Levels in semen samples collected 3.0 to 4.5 hours after oral dosing were 1.68 to 6.43 µmol/L. These values are above the in vitro minimum inhibitory concentration for the human immunodeficiency virus type 1 (HIV-1). Mean serum concentrations at the early and late times after oral dosing were 0.22 to 3.07 µmol/L and 0.10 to 1.42 µmol/L, respectively. Ratios of semen/serum zidovudine levels ranged from 1.3 to 20.4. It is possible that a pH-dependent trapping mechanism, which has been described in the prostate for other antibiotics, was responsible for the relatively high semen levels observed.

(JAMA 1988;259:3023-3026)

Author Affiliations
From the Department of Medicine, St Paul—Ramsey Medical Center, and the St Paul Division of Public Health (Dr Henry); Departments of Laboratory Medicine and Pathology (Ms Chinnock and Dr Balfour) and Pediatrics (Dr Balfour), University of Minnesota Health Sciences Center, Minneapolis; Burroughs Wellcome Co, Research Triangle Park, NC (Drs Quinn and de Miranda); and Pharmaceutical Services, University of Minnesota Hospital and Clinic, Minneapolis (Dr Fletcher).

Footnotes
Reprint requests to Box 437 UMHC, University of Minnesota, Harvard Street at E River Road, Minneapolis, MN 55455 (Dr Balfour).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Decreased Semen Volume and Spermatozoa Motility in HIV-1-Infected Patients Under Antiretroviral Treatment
Bujan et al.
J Androl 2007;28:444-452.
ABSTRACT | FULL TEXT  

Human Organic Anion Transporters and Human Organic Cation Transporters Mediate Renal Antiviral Transport
Takeda et al.
J. Pharmacol. Exp. Ther. 2002;300:918-924.
ABSTRACT | FULL TEXT  

Pharmacokinetic Profiles of Nevirapine and Indinavir in Various Fractions of Seminal Plasma
van Praag et al.
Antimicrob. Agents Chemother. 2001;45:2902-2907.
ABSTRACT | FULL TEXT  

Domestic Cat Model for Predicting Human Nucleoside Analogue Pharmacokinetics in Blood and Seminal Plasma
Jordan et al.
Antimicrob. Agents Chemother. 2001;45:2173-2176.
ABSTRACT | FULL TEXT  

Antiretroviral drug concentrations in semen of HIV-1 infected men
Taylor and Pereira
Sex. Transm. Infect. 2001;77:4-11.
ABSTRACT | FULL TEXT  

A Novel Zidovudine Uptake System in Microglia
Hong et al.
J. Pharmacol. Exp. Ther. 2001;296:141-149.
ABSTRACT | FULL TEXT  

Rat Multispecific Organic Anion Transporter 1 (rOAT1) Transports Zidovudine, Acyclovir, and Other Antiviral Nucleoside Analogs
Wada et al.
J. Pharmacol. Exp. Ther. 2000;294:844-849.
ABSTRACT | FULL TEXT  

Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1
Kashuba et al.
Antimicrob. Agents Chemother. 1999;43:1817-1826.
FULL TEXT  

Effects of Disease Stage and Zidovudine Therapy on the Detection of Human Immunodeficiency Virus Type 1 in Semen
Anderson et al.
JAMA 1992;267:2769-2774.
ABSTRACT  

Targeting AIDS Prevention and Treatment Toward HIV-1--Infected Persons: The Concept of Early Intervention
Francis et al.
JAMA 1989;262:2572-2576.
ABSTRACT  

The Use of HIV Antibody Testing by Physicians-Reply
Henry et al.
JAMA 1988;259:2994-2995.
ABSTRACT